Abstract
Since the first report by Sazerac and Levaditi 1 on the antisyphilitic action of bismuth, this subject has attracted widespread interest. Of the numerous papers on this subject, not one has disputed the fact that this metal has a spirocheticidal action in syphilis of man and experimentally infected animals. There is, however, much uncertainty as to its exact place in the therapy of syphilis. The questions at present in the balance are: the relative value of bismuth as compared with other antisyphilitics, the most effective compound, the dosage, the type of cases in which it should be used, and the correlation of bismuth therapy with other forms of treatment in the same patient. To decide these questions, it seems necessary to obtain more accurate data as to the dosage in experimental animals, more prolonged observation of cases treated by the drug, and a better understanding of its toxicity, its rate
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
